Jump to main content
Jump to site search


T1/T2 Dual functional iron oxide MRI contrast agent with super stability and low hypersensitivity benefited by ultrahigh carboxyl group density

Abstract

Clinical acceptable safety and efficacy are the most important issues for the design and synthesis of iron oxide MRI contrast agent. In order to meet the practical requirements, a kind of low molecular weight PAA-coated Fe3O4 nanoparticles (CS015) with super colloidal stability and low hypersensitivity benefited from ultrahigh carboxyl group density were developed in this study. The constitution and physicochemical properties of the particles were characterized by TEM, XRD, FTIR and TGA. Ultrahigh density of COOH on the particles (33 COOH/nm2) was verified while core size (5.1 nm) and dynamic diameter (41 nm) with a narrow distribution were also achieved. The particles still showed excellent dispersity and stability even after spray-dry or freeze-dry process, high temperature sterilized conditions and long-term storage. The nanoparticles could quickly capture iron ions in bulk solution which was confirmed by ITC results, and the bioactive iron of CS015 was greatly decreased (0.54±0.05 mg/L) compared to commercial available Ferumoxytol, Iron Sucrose and VSOP. Free iron ions release was 1120 times lower than iron toxic concentration. An excellent biocompatability of CS015 with no obvious cytotoxicity and low risk of hypersensitivity has been manifested by cytotoxicity experiments and passive cutaneous anaphylaxis test. T1 and T2-weighted MRI contrast effects both in vitro and in vivo had also been verified which made CS015 a potential dual MRI contrast agent. Furthermore, theoretically calculated conformation was speculated and all the advantages mentioned above were benefited from the three dimensional brush-like texture of CS015. Therefore, these merits endow CS015 nanoplatform a high potential in diagnostic applications as a MRI contrast agent.

Back to tab navigation

Supplementary files

Publication details

The article was received on 01 Jan 2019, accepted on 11 Feb 2019 and first published on 13 Feb 2019


Article type: Paper
DOI: 10.1039/C9TB00002J
Citation: J. Mater. Chem. B, 2019, Accepted Manuscript

  •   Request permissions

    T1/T2 Dual functional iron oxide MRI contrast agent with super stability and low hypersensitivity benefited by ultrahigh carboxyl group density

    H. Gu, C. Miao, F. Hu, Y. Rui and Y. Duan, J. Mater. Chem. B, 2019, Accepted Manuscript , DOI: 10.1039/C9TB00002J

Search articles by author

Spotlight

Advertisements